Safety
blurred vision, toxicities, hyperphosphatemia, retinal detachment, hypophosphatasemia
ADVERSE EVENTS, HYPERPHOSPHATEMIA, RETINAL DETACHMENT
All patients experienced at least one TEAE (Table Common treatment‐emergent adverse events
Among sponsor‐defined clinically notable TEAEs, hyperphosphatemia (median time to onset, 8 days [range, 5–117]) occurred in 24 (77.4%) patients, among whom one (3.2%) was ≥grade 3. The other sponsor‐defined clinically notable TEAEs were all <grade 3 except for blurred vision (grade 3, one [3.2%]). Nail toxicities (median time to onset, 58.5 days [range, 9–138]) were reported in 16 (51.6%) patients, and hypophosphatasemia (median time to onset, 54 days [range, 23–134]) occurred in seven (22.6%) patients, and retinal detachment due to subretinal fluid accumulation (median time to onset, 22 days [range, 21–30]) was found in three (9.7%) patients.Mean blood phosphate among patients in the SS increased above baseline in the first cycle of treatment (increased by 0.84 mmol/L on day 8 and by 1.08 mmol/L on day 15), which decreased to below baseline from cycle 2 to the end of treatment (reduced by 0.03–0.33 mmol/L; Figure 